By Joseph R. Bertino, Andrew J. Dannenberg, Raymond N. DuBois
A variety of investigators have came across elevated degrees of cyclooxygenase-2 (COX-2) in either pre-malignant and malignant tissues. furthermore, animals engineered to be COX-2 poor or taken care of with a selective COX-2 inhibitor confirmed lowered tumor formation and development. the current ebook stories those findings suggesting that COX-2 is a legitimate molecular aim for the prevention and therapy of melanoma. the 1st chapters are dedicated to the epidemiology of nonsteroidal anti inflammatory medicines (NSAIDs) and melanoma, the pharmacology of COX-2 inhibitors and the rules of COX-2 expression in human cancers. along with, the ebook incorporates a sequence of chapters studying the hyperlink among COX-2 and melanoma in particular organs (e.g. dermis, breast, cervix, digestive tract, lung, etc.). moreover, numerous scientific trials assessing the possibility of COX-2 inhibitors for fighting and treating melanoma are defined.
Read or Download Cox-2: a new target for cancer prevention and treatment PDF
Similar cancer books
From its advent, oncological chemotherapy has been weighted down via its negative selectivity simply because so much antiproliferative medicines are poisonous not just to tumor cells but in addition to big populations of the body’s non-neoplastic cells. the ensuing issues of unwanted effects are compounded via problems in predicting the specified efficiency of chemotherapy in person sufferers.
The Analog strength in melanoma Chemotherapy within the usa and Japan S. ok. Carter Northern California melanoma application, 1801 web page Mill street, development B, Suite 2 hundred, united states - Palo Alto, CA 94304 The bilateral collaborative software in melanoma examine among Japan and the us is among the oldest courses of this sort.
- Cure for Cancer: The Rick Simpson Protocol
- A Guide To First Aid In The Work Place
- Rectal Cancer Surgery: Optimisation — Standardisation — Documentation
- Trends in Breast Cancer Prevention
Additional resources for Cox-2: a new target for cancer prevention and treatment
Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO: Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study. Gastroenterology 1994;107:117–120. Moody GA, Jayanthi V, Probert CS, MacKay H, Mayberry JF: Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179–1183. Lindberg BU, Broome U, Persson B: Proximal colorectal dysplasia or cancer in ulcerative colitis.
Bansal P, Sonnenberg A: Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996;91:44–48. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635–639. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
Rofecoxib is also well absorbed in the GI tract with peak plasma concentrations occurring 2–3 h after oral administration . Similarly, valdecoxib is well absorbed with peak plasma concentration occurring within 2 h. , administration of celecoxib with high-fat meals extends Tmax by 1–2 h . Metabolism and Excretion Celecoxib is converted by hepatic biotransformation to hydroxy, carboxylic acid and glucuronidate derivatives. Oxidative metabolism by the cytochrome P450 (CYP) 2C9 isoenzyme is the primary metabolic pathway, resulting in oxidation of the methyl moiety to a carboxyl group; this is followed by glucuronidation of this carboxyl metabolite to form the major metabolite, SC-62807.